CFDA Approves Venus Medtech's Minimally Invasive Aortic Valve Implant

Venus Medtech of Hangzhou received CFDA registration to market its transcatheter aortic valve system in China. The Venus A-valve, which was specifically designed for China patients, is the first Transcatheter Aortic Valve Implantation device approved for China use. For inoperable/high-risk patients, the device offers a less invasive alternative than the usual open-heart surgery and cardiopulmonary bypass surgery. Because of the minimally invasive technique, patients recover more quickly. More details.... Share this with colleagues: // //